Smith Salley Wealth Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Smith Salley Wealth Management’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-986	Closed	-$32K	–	264
2021 Q3	$32K	Sell	986 -7,440	-88%	-$241K	﹤0.01%	251
2021 Q2	$361K	Buy	8,426 +7,440	+755%	+$306K	0.03%	204
2021 Q1	$48K	Buy	986 +721	+272%	+$39.6K	﹤0.01%	230
2020 Q4	$9K	Hold	265	–	–	﹤0.01%	213
2020 Q3	$11K	Hold	265	–	–	﹤0.01%	189
2020 Q2	$12K	Buy	+265	New	+$14.1K	﹤0.01%	190

Other funds holding FRTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Smith Salley Wealth Management's FRTX Position: Q4 2021 in Review

Smith Salley Wealth Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2021, closing a stake of 986 shares — an estimated $32K sold.

Smith Salley Wealth Management first reported a position in FRTX in Q2 2020 and held it in 6 quarters. The position peaked at $361K in Q2 2021. 30 funds tracked by Wall St. Rank hold FRTX as of Q4 2021.

Smith Salley Wealth Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Smith Salley Wealth Management sold 986 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $32K.
Smith Salley Wealth Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Smith Salley Wealth Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $361K in Q2 2021.
30 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Smith Salley Wealth Management's 13F filing for Q4 2021, filed 10 Feb 2022.